CN104225627B - The leukocytic immunity globulin sample receptor subfamily B member 4 function and application in treatment atherosclerosis - Google Patents
The leukocytic immunity globulin sample receptor subfamily B member 4 function and application in treatment atherosclerosis Download PDFInfo
- Publication number
- CN104225627B CN104225627B CN201410514351.4A CN201410514351A CN104225627B CN 104225627 B CN104225627 B CN 104225627B CN 201410514351 A CN201410514351 A CN 201410514351A CN 104225627 B CN104225627 B CN 104225627B
- Authority
- CN
- China
- Prior art keywords
- lilrb4
- apoe
- mice
- atherosclerosis
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of leukocytic immunity globulin sample receptor subfamily B member 4(LILRB4) function and application in treatment atherosclerosis, belong to function and the application of gene.The present invention is with ApoE‑/‑Mice and LILRB4‑/‑ApoE‑/‑Mice is experimental subject, obtains Atherosclerosis Model by high fat diet induction, and result shows and ApoE‑/‑Mice contrasts, and LILRB4 genetic flaw significantly increases the plaque area of aorta, reduces the stability of aortic sinus speckle, is significantly degrading inflammatory reaction.This shows LILRB4 function in atherosclerosis, is mainly reflected in LILRB4 and has the effect that suppression Aortic Plaque is formed, and particularly LILRB4 can suppress atherosclerotic effect.For the above-mentioned functions of LILRB4, LILRB4 can be used for preparation prevention, alleviates and/or treat atherosclerotic medicine.
Description
Technical field
The invention belongs to function and the application of gene, be specifically related to a kind of leukocytic immunity globulin sample receptor subfamily B member 4(LILRB4) function and application in treatment atherosclerosis, specifically LILRB4 in preparation prevention, alleviate and/or treat in atherosclerotic medicine and apply.
Background technology
Cardiovascular and cerebrovascular disease be main lethal in many developed countries because of, sickness rate and fatality rate in China raise the most year by year.The basis of cardiovascular and cerebrovascular disease is atherosclerosis (Atheosclersisis, AS), and atherosclerosis can make ductus arteriosus wall thicken, hardening, luminal stenosis, causes a lot of cardiocerebrovasculaevents events to occur.And the coronary artery acute stenosis that causes of the rupturing of atherosclerosis unstable spot, hematoblastic gathering and thrombosis and obturation are the major reasons causing acute coronary syndrome (acute coronary syndrome, ACS).
Atherosclerosis is multiple gene, a kind of chronic inflammation disease that risk factor and immunologic mechanism participate in jointly, inflammatory and immune response locally and systemically plays an important role in atherosclerosis generation evolution, inherent immunity and adaptive immunity participate in regulating atherosclerotic lesion jointly, show as big on pathology, medium-sized artery many places speckle is formed, it is apt to occur in blood shunt, the regions such as tremulous pulse bending and arterial branch, its characteristics of lesion is that in blood, lipid deposits at endarterium, cause inner membrance stove fibrous thickening, focus deep is the medicated porridge sample material formed by slough and extracellular lipid pond.Atheromatous plaque also exists panimmunity cell, wherein most commonly seen with macrophage and T cell, in addition with a small amount of dendritic cell (Dentritic cell, DC), natural killer cell (natural killer cell, NK cell) and mastocyte (mast cell) etc., occasionally there is bone-marrow-derived lymphocyte.
The macroscopic damage of atherosclerosis earliest period is fatty streaks, is mainly made up of the Macrophage derived foamy cell that intake of a large amount of cholesterol.Mononuclear cell in blood circulation is attached to reactive endothelial cells at tremulous pulse damageable zone, starts the formation of fatty streaks, and the chemistry that the mononuclear cell sticked the most locally is produced is ingratiated with the attraction of molecule and moved under inner membrance, and is divided into macrophage further.A large amount of cholesterol esters, in macrophage inner accumulated, form foam cell, and this is atherogenesis characteristic pathological physiological process in early days.Atherosclerotic is multifactor coefficient result, and the atherosclerosis risk sexual factor having now been found that is a lot, but related pins is the most undesirable to treatment and control effect, and blood fat reducing and anti-inflammatory treatment are current topmost remedy measures.
Immunoglobulin superfamily (IgSF) receptor is an important receptor of class of Macrophage Surface, take part in the immune disease of multiple macrophage induction, and plays a significant role in graft-rejection.IgSF receptor can conduct inhibition or excitatory signal, makes the function of macrophage raise or lower, thus keeps immune homeostasis and produce effective immunne response.Cell immunoglobulin sample receptor (LILR) belongs to IgSF family, can be combined with major histocompatibility complex (MHC) I class or correlation molecule, is expressed in lymphocyte and medullary cell film surface.LILR contains 5 Inhibitory receptor (LILRB1-LILRB5), 3 excitatory receptors (LILRA1-LILRA3), and these receptors have 2-4 IgSF domain outside born of the same parents, and tyrosine residue is contained in cytoplasmic region, can phosphorylation play biological action.LILRB4 is also referred to as ILT3, LIR-5, CD85k, chromosome 19q 13.4 encode.Study confirmation LILRB4 and participate in immunologic tolerance (Hao Cheng, Fiyaz Mohammed, Gol Nam, et al. Crystal
Structure of Leukocyte Ig-like Receptor LILRB4 (ILT3/LIR-5/
CD85k) A MYELOID INHIBITORY RECEPTOR INVOLVED IN IMMUNE
TOLERANCE. J Biol Chem. 2011;286 (20): 18,013 18025.).Based on the studies above basis, it is considered that LILRB4 may play key player in the characteristic pathological physiological process of atherogenesis, but its biological function in the characteristic pathological physiological process of atherogenesis and possible mechanism of action not yet illustrate.
Mice and genetic engineering mice resource are one of most important animal models in field such as current disease mechanisms research, gene functional research, medicine initiative, are also the necessary conditions of these field innovation researches.Each molecule link during utilizing genetic engineering mice to manage for Atheromatosis is studied, and to the molecular mechanism illustrated in atherosclerosis generation evolution, the molecular target finding treatment of atherosclerosis has great importance.
Summary of the invention
It is an object of the invention to determine the expression of LILRB4 and atherosclerotic mutual relation, it is provided that one for preventing, alleviate and/or treat the new application of atherosclerotic target gene LILRB4.
The purpose of the present invention is achieved through the following technical solutions:
Expression and the atherosclerotic relation of the LILRB4 that present invention determine that are as follows:
1. LILRB4 gene knockout significantly increases atherosclerotic plaque area
The present invention is with ApoE gene knockout (ApoE-/-) mice is with LILRB4/ApoE is dual-gene knocks out (LILRB4-/-ApoE-/-) mice is experimental subject, obtains atherosclerosis mouse model (AS) by low fat feedstuff and high lipid food diet induced respectively.Result shows ApoE-/-And LILRB4-/-ApoE-/-Mice passes through low fat feed diet, and aorta tree has a small amount of speckle to be formed；After high lipid food diet, plaque area dramatically increases, LILRB4-/-ApoE-/-The aorta tree of mice, the plaque area of aortic sinus are all remarkably higher than ApoE-/-Mice (Fig. 1-2).
2. LILRB4 gene knockout significantly reduces the stability of aortic sinus speckle
The present invention is with ApoE gene knockout (ApoE-/-) mice is with LILRB4/ApoE is dual-gene knocks out (LILRB4-/-ApoE-/-) mice is experimental subject, obtain atherosclerosis mouse model (AS) by high lipid food diet induced, the stability of aortic sinus speckle is studied.Result shows that LILRB4 gene knockout significantly increases content and the area of necrotic center of macrophage in aortic sinus speckle, decreases content and the collagen component content of smooth muscle cell in speckle, and entirety reduces the stability (Fig. 3) of aortic sinus speckle.
3. LILRB4 gene knockout is significantly degrading inflammatory reaction
The present invention is with ApoE gene knockout (ApoE-/-) mice is with LILRB4/ApoE is dual-gene knocks out (LILRB4-/-ApoE-/-) mice is experimental subject, obtains atherosclerosis mouse model (AS) by high lipid food diet induced, the expression to the inflammatory factor of aortic sinus speckle is studied.Result shows that LILRB4 gene knockout significantly increases the proinflammatory factors such as ICAM-1 and IL-6 of aortic sinus speckle, reduces IL-10 etc. and presses down the expression (Fig. 4) of the scorching factor.
When being understood generation atherosclerosis by result above, LILRB4 genetic flaw adds aorta tree plaque area, weakens the stability of aortic sinus speckle, is significantly degrading inflammatory reaction.Therefore LILRB4 has the effect that suppression atherosclerosis occurs to develop, and prevents and treats atherosclerotic novel targets for research and New Policy provides theoretical foundation and Clinical Basis.
Above-mentioned functions for LILRB4, it is provided that the application of a kind of LILRB4, is mainly reflected in LILRB4 and prevents in preparation, alleviate and/or treat the application in atherosclerotic medicine.
One is prevented, is alleviated and/or treat atherosclerotic medicine, comprises LILRB4 and maybe can express the carrier of LILRB4.
The present invention has such advantages as relative to prior art and effect:
1. present invention discover that the New function of LILRB4 gene, i.e. LILRB4 can significantly inhibit atherosclerotic effect.
2. based on the function in LILRB4 suppression atherosclerosis, provide basis for developing atherosclerotic medicine, the medicine can be used for preparation prevention, alleviating and/or treat in atherosclerosis.
Accompanying drawing explanation
Fig. 1 is ApoE-/-And LILRB4-/-ApoE-/-The aorta tree oil red O stain of mice and plaque area cartogram, result shows that LILRB4 gene knockout significantly increases the plaque area (NS: there was no significant difference) of aorta tree.
Fig. 2 is ApoE-/-And LILRB4-/-ApoE-/-Mouse aorta hole HE dyeing and plaque area statistics block diagram, result shows that LILRB4 gene knockout significantly increases plaque area (*: the p ＜ 0.05 vs HFD ApoE of aortic sinus-/-Group).
Fig. 3 is ApoE-/-And LILRB4-/-ApoE-/-Necrotic center, collagen component, macrophage and the dyeing of smooth muscle cell content and result statistics block diagram in the aortic sinus speckle of mice, result shows that LILRB4 gene knockout dramatically increases content and the area of necrotic center of macrophage in aortic sinus speckle, decreases content and collagen component content (*: the p ＜ 0.05 vs HFD ApoE of smooth muscle cell in speckle-/-Group).
Fig. 4 is ApoE-/-And LILRB4-/-ApoE-/-The expression immunofluorescence dyeing of the inflammatory factor such as ICAM-1, IL-6, IL-10 and result statistics block diagram in the aortic sinus speckle of mice, result shows that LILRB4 gene knockout significantly increases the expression of proinflammatory factor ICAM-1 and IL-6 of aortic sinus speckle, reduces expression (*: the p ＜ 0.05 vs HFD ApoE pressing down scorching factor IL-10-/-Group).
Detailed description of the invention
Below in conjunction with embodiment and accompanying drawing, the present invention is described in further detail, but embodiments of the present invention are not limited to this.
Animal for research and raising
Laboratory animal kind, sex, week old and source: ApoE gene knockout (ApoE-/-) mice is with LILRB4/ApoE is dual-gene knocks out (LILRB4-/-ApoE-/-) mice, male, 8 week old, body weight 19-25g.ApoE knock out mice (ApoE-/-, purchased from Jackson
Laboratory, article No. 002052)；LILRB4-/-ApoE-/-Mice is obtained by LILRB4 knock out mice (purchased from RIKEN company of Japan, article No.: RBRC02692) and the hybridization of ApoE knock out mice.
Laboratory animal feed formula: high lipid food (HFD, purchased from Fukang bio tech ltd of Beijing China, by AIN-76 A Western Diets formula, percent of calories: protein 15.8%, fat 40%, carbohydrate 44.2%)；Low fat feedstuff (NC, purchased from Fukang bio tech ltd of Beijing China, article No. D12450B): percent of calories: protein 20%, carbohydrate 70%, fat 10%.
Animal feeding and environmental condition: all of experiment mice is all raised at angiocardiopathy institute of Wuhan University SPF level Animal House (credit number: SYXK(Hubei Province): 2009-0053).Alternately illumination in every 12 hours, temperature 24 ± 2 DEG C, humidity 40%-70%, mice freely drinks water feed.
Embodiment 1
Rat aorta is atherosis, and model (AS) obtains
1. laboratory animal packet: select 8 week old, body weight 19-25g, male, ApoE-/-Mice and LILRB4-/-ApoE-/-Mice, gives high lipid food (Western Diets, HFD) and low fat feedstuff (Normal respectively
Chow, NC) raise, ApoE-/-HFD group, ApoE-/-NC group, LILRB4-/-ApoE-/-
HFD group, LILRB4-/-ApoE-/-NC group totally 4 groups, often organize each 20.
2. Atherosclerosis Model is by high lipid food induction operating process:
Use ApoE-/-Mice and LILRB4-/-ApoE-/-Mice, sets up AS model, carries out phenotype correlation analysis, specifies the effect that LILRB4 gene pairs atheromatosis plays.Mice is from the beginning of 8 week old, and the omnidistance high lipid food of HFD group is fed 28 weeks and put to death and collect sample, and the omnidistance low fat forage feed of NC group is put to death and collects sample for 28 weeks.
Embodiment 2
AS model mice plaque area measures
1. mice end tissue sampling eventually
Mice feeds high fat or low fat feedstuff until when 28 weeks, weighing, using 3% pentobarbital sodium, 90mg/kg anesthetized mice, it is fixed on material drawing board with syringe needle, moistens mice skin of chest abdomen with gauze, cut off thoracic cavity with eye scissors, expose heart, cut off right auricle, the syringe needle of transfusion device is lunged left ventricle, slowly inject 10-15mL PBS with 50mL syringe, treat that right auricle effluent is limpid, change 4% paraformaldehyde and continue to inject 10-15mL.After perfusion terminates, remove splanchnocoel internal organs, only retain heart.Mice is placed under microscope, separates fascia, fatty tissue around aortic arch, cut heart in ascending aorta initial part, cut off in the middle part of thoracic aorta, and cut off at about 3mm under neck summation clavicle, aortic arch is put in above-mentioned EP pipe.
2. aorta tree plaque area measures
Aorta tree is placed in fixing → pure water rinsing 30min → 60% isopropanol overnight in 4% paraformaldehyde and processes 10 min → oil red O dye liquor (company sigma, article No. 00625) dyeing 60min → 60% isopropyl alcohol 1min × 3 time are to removing remaining outer wall fat → be laid on black dissection stencil plate by tremulous pulse dye under clean background → anatomical lens, take pictures with digital camera after dyeing, and use Image-Pro Plus 6.0 image analysis software to carry out plaque area quantitative determination (oil red O stock solution=0.5 gram oil red O+100 milliliter 100% isopropanol, oil red O dye liquor (working solution): V(oil red O stock solution)/V(H2O)=3/2).
Aorta tree plaque area (%)=speckle gross area/aorta tree gross area * 100%.
3. pathological tissue processes
Prepared by 3.1 paraffin specimens
In 4% paraformaldehyde overnight fixing after, aortic arch filter paper is carefully wrapped, in case spilling from embedding frame gap.Flowing water puts into dewaterer after rinsing 30min, 30% ethanol 15min → 50% ethanol 15min → 75% ethanol 15min → 85% ethanol 15min → 95% ethanol 15min → 100% ethanol 15min → 100% ethanol 15min → dimethylbenzene 15min → dimethylbenzene 15min → paraffin 30min → paraffin 30min.After aortic arch has been dehydrated, taking out from dewaterer, aortic arch lies low in paraffin.
3.2 aortic tissue sections
Use microtome that aortic sinus paraffin specimen is cut into slices (slice thickness 5 μm).
4. aortic sinus plaque area measures
nullHaematoxylin eosin stains (HE dyeing): take aortic sinus paraffin white tiles 65 DEG C baking 30 minutes → dimethylbenzene 5 minutes × 3 times → 100% ethanol 1 minute → 95% ethanol 1 minute → 70% 1 minute → pure water of ethanol rinsing (not hanging with the globule on slide as standard) → get rid of the moisture on most microscope slide，Haematoxylin solution (Zhuhai shellfish rope，BA-4021) 5 minutes → tap water rinse (removing haematoxylin loose colour on slide) → 1% acidic alcohol 1-3 second → tap water rinse (removing acidic alcohol on slide) → Scott liquid (sodium bicarbonate 0.35g is contaminated，Magnesium sulfate 2g，Distilled water 100mL) 1 minute → tap water embathes (removing the Scott liquid on slide) → get rid of the moisture being all on slide，Yihong solution (Zhuhai shellfish rope，BA-4024) 10 seconds → pure water of dyeing rinsing (removing the loose colour in Yihong on slide) → 70% ethanol once → 95% ethanol once → 100% ethanol 30 seconds，3 times → dimethylbenzene 2 minutes，3 times → take advantage of dimethylbenzene the most dry time mounting (with bubble-free of cutting into slices as principle) → fume hood in dry up，Microscope is taken pictures.
HE dyeing picture statistics: directly by Image-Pro Plus 6.0 image analysis software circle aortic sinus plaque area.
By aorta tree oil red O stain can substantially assess that the upper atheromatous plaque of aorta tree formed number, distribution situation and the size of plaque area.Fig. 1 is mice AS model aorta posterior tree oil red O stain result figure, and brachiocephalic trunk and aortic sinus are the most obvious positions of atheromatous plaque, ApoE-/-And LILRB4-/-ApoE-/-Mice passes through low fat feed diet, and aorta tree just has a small amount of speckle to be formed；After being induced by high fat diet, plaque burden dramatically increases, LILRB4-/-ApoE-/-The aorta tree plaque area of mice is noticeably greater than ApoE-/-Mice.Fig. 2 is mice AS model posterior sinus of Valsalva HE coloration result figure, and result shows LILRB4 after high fat diet-/-ApoE-/-The plaque area of the aortic sinus of mice is also significantly greater than ApoE-/-Mice.Result above shows that LILRB4 gene knockout significantly increases atherosclerotic plaque area.
Embodiment 3
The mensuration of AS model mice plaque stability
1. the size of aortic sinus necrotic center measures
Haematoxylin eosin stains (HE dyeing), method, with embodiment 2.4, is chosen the tissue microscope containing cholesterol crystal, acellular core fibre structure and is taken pictures.
The area estimation of necrotic center: use Image-Pro Plus 6.0 image analysis software circle necrotic center area.
2. aortic sinus collagen component assay:
Picro-Sirius red (PSR) dyes, mainly comprise the following steps: take aortic sinus paraffin white tiles 55 DEG C baking 30min → dimethylbenzene 2min, 3 times → 100% ethanol 1min → 95% ethanol 1min → 70% ethanol 1min → flowing water rinses 10min → distilled water 1min → mass fraction 0.2% phosphomolybdic acid 2min → 0.1% sirius red picric acid solution and drips in tissue, dye in wet box 90min → remove residul liquid-removing → 0.01N hydrochloric acid 4s → 70% ethanol 1 time → 90% ethanol 1 time → 100% ethanol 30s, 3 times → dimethylbenzene 2min, 3 times → take advantage of the most dry coverslip mounting immediately of dimethylbenzene, microscope is taken pictures.
Collagen ratio measuring: use Image-Pro Plus 6.0 image analysis software circle redness area of collagen, collagen ratio (%)=area of collagen/plaque area * 100%.
3. the expression of aortic sinus macrophage and smooth muscle cell mark measures
Immunofluorescence dyeing detection aortic sinus macrophage marker CD68, smooth muscle cell mark SMA(Smooth Muscle Actin) expression.Required anti-information a: CD68(MCA1957;
1:100; rat;AbD Serotec), SMA(ab5694; 1:100; rabbit;Abcam)；Required two anti-information: Alexa Flour 568 goat anti-rat IgG(A11077；Invitrogen), Alexa Fluor 488-conjugated goat
Anti-rabbit IgG(A11008；Invitrogen).
Mainly comprise the following steps:
1) roasting sheet: aortic sinus paraffin white tiles is placed in more than 30min in baking box.
2) dewaxing: dimethylbenzene 5min × 3 time.
3) hydration: 100% ethanol 5min × 2 time；95% ethanol 5min；70% ethanol 5min；DdH2O embathes 5min × 2 time.
4) citrate tissue antigen recovery (Pressure method): take a certain amount of pH6.0 citrate antigen retrieval working solution in repairing in box, put in pressure cooker, big fire is heated to boiling, tissue slice after dewaxing hydration is placed in reparation box, cover pot cover, buckle pressure valve, continue to be heated to jet, after starting timing 5min, take out and repair box；Room temperature places 20min, takes out section after natural cooling.
5) ddH2O rinses 5min × 2 time, and PBS rinses 5min × 2 time.
6) groupization stroke circle, drips 10% sheep blood serum (GTX27481, GeneTex) and closes, and closes 60min for 37 DEG C in wet box.
7) abandoning confining liquid, the one of dropping proper proportion dilution resists, 4 DEG C of overnight incubation, and 37 DEG C of rewarming 30min discard one and resist, and PBS washes 10min × 3 time.
8) dropping two resists, and hatches 60min for 37 DEG C in wet box, discards two and resists, and PBS embathes 5min × 3 time.
9) SlowFade
Gold antifade reagent with DAPI(S36939, Invitrogen) mounting.
10) viewed under fluoroscopy, takes pictures.
Fluorescent quantitation is added up: use Image-Pro Plus 6.0 image analysis software to measure Positive Cell Counts, CD68/SMA(%)=positive cell number/plaque area * 100%.
Macrophage is most important cell component in speckle, differentiate after it is subcutaneous in mainly having blood circulation mononuclear cell to enter, Monocytes/Macrophages can secrete multiple adhesion, chemotactic factor such as cell adhesion molecule (ICAM-1), MCAF (MCP-1) etc., promote the entrance of speckle inner cell, in addition macrophage also can secrete multiple matrix metalloproteinase (MMPs), reduce area of collagen in speckle, thus destroy the stability of speckle；Smooth muscle cell can secrete various kinds of cell substrate, is the cell source of atheromatous plaque endocrine collagen, and Main Function is to repair destroyed cellular stromal component thus plays a protective role；Collagen component is most important extracellular matrix in speckle, is also the main component of fibrous cap, has the impact of anti-blood flow and prevents the effect of plaque rupture, is also the important evaluation index safeguarding plaque stability.
Fig. 3 is ApoE-/-Mice and LILRB4-/-ApoE-/-The analysis result figure of the aortic sinus speckle inclusions of mice.The visible LILRB4 of aortic sinus HE dyeing-/-ApoE-/-The necrotic center area of mice is significantly greater than ApoE-/-Mice；PSR coloration result shows the model after high fat diet, LILRB4-/-ApoE-/-The collagen ratio of group mice is significantly lower than ApoE-/-Mice；Immunofluorescence sends out observation macrophage marker CD68 at LILRB4-/-ApoE-/-Expression in mice speckle is then significantly higher than ApoE-/-Mice；Smooth muscle cell mark SMA is at LILRB4-/-ApoE-/-Expression in mice speckle is significantly lower than ApoE-/-Mice.Result above shows that LILRB4 gene knockout dramatically increases content and the area of necrotic center of macrophage in aortic sinus speckle, reduces content and the collagen component content of smooth muscle cell in speckle；Therefore LILRB4 gene knockout can reduce the stability (Fig. 3) of aortic sinus speckle.
Embodiment 4
The mensuration of inflammatory Cytokines Expression in AS model mice speckle
The expression of the inflammatory factors such as immunofluorescence dyeing detection aortic sinus ICAM-1, IL-6, IL-10.Required anti-information a: ICAM-1(AF796；1:100；goat；R&D systems), IL-6(AF-406-NA；1:100；goat；R&D systems), IL-10(AF-217-NA；1:100；goat；R&D systems)；Required two anti-information: Alexa Flour 568 donkey anti-goat IgG(A11057；Invitrogen).
Mainly comprise the following steps: see embodiment 3.3.
Fluorescent quantitation is added up: uses Image-Pro Plus 6.0 image analysis software that positive cell carries out absorbance (IOD) and measures.
Inflammatory reaction is one of principal element of causing atheromatous plaque to rupture.The a large amount of cytokine of proinflammatory cytokine secretion such as interleukin-6 (IL-6), interleukin 10 (IL-10) etc. may result in the activation of endotheliocyte, the hypertrophy apoptosis of smooth muscle cell and the progress of medicated porridge sample pathological changes.Adhesion, chemotactic factor that impaired endotheliocyte and Monocytes/Macrophages are secreted are the key factors that transmitting inflammation cell is assembled to atheromatous plaque.The expression being observed the inflammatory factors such as ICAM-1, IL-6, IL-10 by immunofluorescence dyeing is changed, result shows that LILRB4 gene knockout significantly improves the expression of proinflammatory factor ICAM-1, IL-6 in aortic sinus speckle, reduces IL-10 and presses down the expression (Fig. 4) of inflammatory factor.
Above-described embodiment result shows, ApoE-/-Mice and LILRB4-/-ApoE-/-Mice issues lively pulse atherosclerosis, and ApoE in the induction of high fat diet-/-Mice is compared, and the dual-gene Aortic Plaque area knocking out rear mice of LILRB4/ApoE dramatically increases, and plaque stability reduces, and inflammatory reaction substantially increases the weight of.These results indicate that LILRB4 can significantly inhibit the formation of Aortic Plaque and atherosclerotic develop.Present invention demonstrates that LILRB4 has important protective effect in Atherosclerosis Model, it can be used for preparation prevention, alleviates and/or treat the medicine of atheromatosis.
Above-described embodiment is the present invention preferably embodiment; but embodiments of the present invention are also not restricted to the described embodiments; the change made under other any spirit without departing from the present invention and principle, modify, substitute, combine, simplify; all should be the substitute mode of equivalence, within being included in protection scope of the present invention.
Claims (1)
1. a LILRB4 prevents in preparation, alleviates and/or treat the application in atherosclerotic medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410514351.4A CN104225627B (en) | 2014-09-29 | 2014-09-29 | The leukocytic immunity globulin sample receptor subfamily B member 4 function and application in treatment atherosclerosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410514351.4A CN104225627B (en) | 2014-09-29 | 2014-09-29 | The leukocytic immunity globulin sample receptor subfamily B member 4 function and application in treatment atherosclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104225627A CN104225627A (en) | 2014-12-24 |
| CN104225627B true CN104225627B (en) | 2016-09-14 |
Family
ID=52215096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410514351.4A Active CN104225627B (en) | 2014-09-29 | 2014-09-29 | The leukocytic immunity globulin sample receptor subfamily B member 4 function and application in treatment atherosclerosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104225627B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11906519B2 (en) | 2016-07-29 | 2024-02-20 | The Board Of Regents Of The University Of Texas System | Methods for identifying LILRB-blocking antibodies |
| CN111560425A (en) * | 2019-10-14 | 2020-08-21 | 华中科技大学同济医学院附属协和医院 | Application of sFgl2 in detection, prevention, alleviation and treatment of atherosclerotic diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273485C (en) * | 2002-08-19 | 2006-09-06 | 第二军医大学免疫学研究所 | Immunoglobulin sample receptor originated from human dendritic cell, its coding sequence and application |
| CN100480263C (en) * | 2003-06-27 | 2009-04-22 | 浙江大学免疫学研究所 | Immunosuppressive receptor derived from dendritic cell, coding sequence and uses thereof |
| CN101830978A (en) * | 2009-03-09 | 2010-09-15 | 中国科学院微生物研究所 | Human immunoglobulin-like receptor mutant and application thereof |
| WO2013181438A2 (en) * | 2012-05-30 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating pro-inflammatory immune response |
-
2014
- 2014-09-29 CN CN201410514351.4A patent/CN104225627B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104225627A (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Choi et al. | The new era of the lymphatic system: no longer secondary to the blood vascular system | |
| Shin et al. | TH2 cells and their cytokines regulate formation and function of lymphatic vessels | |
| CN105101989B (en) | The inhibitor that the extracellular trap baiting net of leucocyte is formed | |
| CN106074468B (en) | Cinnamic acid can induce the purposes in vegf expression and the inducer of secretion in preparation | |
| CN104225627B (en) | The leukocytic immunity globulin sample receptor subfamily B member 4 function and application in treatment atherosclerosis | |
| Hu et al. | New insights into ion regulation of cephalopod molluscs: a role of epidermal ionocytes in acid-base regulation during embryogenesis | |
| De Boever et al. | Characterization of an intravenous lipopolysaccharide inflammation model in broiler chickens | |
| CN103784973B (en) | The function and application of IRF9 gene in atherosclerosis | |
| CN104056282B (en) | The application in hepatic ischemia-reperfusion injury of the Mindin gene | |
| CN103784971B (en) | Function of IRF (Interferon Regulatory Factor) 3 gene in atherosclerosis and application of inhibitor of IRF3 gene | |
| CN103784975B (en) | Function of IRF (Interferon Regulatory Factor) 7 in atherosclerosis and application of inhibitor of IRF7 | |
| Klećkowska-Nawrot et al. | Histology, histochemistry and fine structure of the Harderian gland, lacrimal gland and superficial gland of the third eyelid of the European bison, Bison bonasus bonasus (Artiodactyla: Bovidae) | |
| CN104324389B (en) | The blood shearing force response protein 1 function and application in treatment atherosclerosis | |
| Lahnsteiner | Differences in immune components of blood, spleen and head kidney between diploid and auto-and allotriploid Salmonidae | |
| CN103784943B (en) | Function and application of interferon regulatory factor 4 (IRF4) in scaffold and endarterectomy restenosis | |
| CN104258395B (en) | Functions and applications of nucleotide synthetase CAD in treatment of atherosclerosis | |
| CN104258419A (en) | Applications of interferon regulatory factor 1 gene in treatment of atherosclerosis | |
| CN104383561A (en) | Function and application of signal regulatory protein 1 treating atherosclerosis | |
| CN104232732B (en) | The function and application of MAPK signal integrating kinase 2 in treatment atherosclerosis | |
| CN104324390B (en) | The application in treatment atherosclerosis of the Mindin gene | |
| CN104324388A (en) | Application of interferon regulatory factor 4 gene in treatment of atherosclerosis | |
| CN104198697B (en) | Centrifugal force and shear stress response gene 1(RECS1) treating the function and application in angiostenosis after damage | |
| CN104225597A (en) | Function and application of MAPK (mitogen-activated protein kinase) signal-integrating kinase 1 in treatment of atherosclerosis | |
| CN103784945B (en) | Function and application of IRF3 (Interferon Regulatory Factor 3) to restenosis after stenting and carotid endarterectomy | |
| CN104258397A (en) | Function and application of Dickkopf-3 for treating atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191121 Address after: 430040 No.1, floor 1, No.17, eleven village, Changqing Garden, Dongxihu District, Wuhan City, Hubei Province (18) Patentee after: Wuhan Dafeng Biotechnology Co., Ltd Address before: 430072 Hubei Province, Wuhan city Wuchang District of Wuhan University Luojiashan Patentee before: WuHan University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191218 Address after: 430014 3119, floor 3, building 9, Guanggu science and technology port, 18 huashiyuan North Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan linyijia Gene Technology Co., Ltd Address before: 430040 No.1, floor 1, No.17, eleven village, Changqing Garden, Dongxihu District, Wuhan City, Hubei Province (18) Patentee before: Wuhan Dafeng Biotechnology Co., Ltd |
|
| TR01 | Transfer of patent right | ||
| CP03 | Change of name, title or address |
Address after: 430076 room 002, 16 / F, building D2, phase III, software new town, No. 8, Huacheng Avenue, Wuhan East Lake New Technology Development Zone, Wuhan, Hubei Province Patentee after: Wuhan Huikang Gene Technology Co.,Ltd. Address before: Room 3119, 3 / F, building 9, Guanggu science and technology harbor, 18 huashiyuan North Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430014 Patentee before: Wuhan linyijia Gene Technology Co.,Ltd. |
|
| CP03 | Change of name, title or address |